Search research articles
Contact Us
Filters
Showing results (401-410 of 481) with videos related to
Page
of 49
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
October 21, 2005
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
Steven A Rosenberg, Richard M Sherry, Kathleen E Morton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
Shivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Lancet (London, England)
|
October 17, 2014
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 8, 2019
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas, Rasa Vilimas, Christopher Trindade, et al.
Clinical & Experimental Metastasis
|
September 29, 2011
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain
Yongzhen Qian, Emily Hua, Kheem Bisht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2020
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Changqing Xie, Austin G Duffy, Gagandeep Brar, et al.
The Lancet. Oncology
|
January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
Arun Rajan, Corey A Carter, Arlene Berman, et al.
The Oncologist
|
March 11, 2022
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer
Jason M Redman, Yo-Ting Tsai, Benjamin A Weinberg, et al.
Blood
|
March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L Piekarz, Robin Frye, H Miles Prince, et al.
Page
of 49
Search research articles
Search
Showing results (401-410 of 481) with videos related to
Sort By:
Page
of 49
Journal of Immunology (Baltimore, Md. : 1950)
|
October 21, 2005
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
Steven A Rosenberg, Richard M Sherry, Kathleen E Morton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
Shivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Lancet (London, England)
|
October 17, 2014
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 8, 2019
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas, Rasa Vilimas, Christopher Trindade, et al.
Clinical & Experimental Metastasis
|
September 29, 2011
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain
Yongzhen Qian, Emily Hua, Kheem Bisht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2020
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Changqing Xie, Austin G Duffy, Gagandeep Brar, et al.
The Lancet. Oncology
|
January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
Arun Rajan, Corey A Carter, Arlene Berman, et al.
The Oncologist
|
March 11, 2022
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer
Jason M Redman, Yo-Ting Tsai, Benjamin A Weinberg, et al.
Blood
|
March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L Piekarz, Robin Frye, H Miles Prince, et al.
Page
of 49